// App-Quantinova.ai

2114 : Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study

Researchers

Presenter

  • Iain B McInnes

Principal Investigators

  • Enrique R Soriano

  • Lai-shan Tam

  • Natalie Shiff

  • May Shawi

  • Emmanouil Rampakakis

  • Jeffrey Curtis

Medical Centers

  • Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

  • The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada

  • University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham, AL

Locations

  • United Kingdom

  • Argentina

  • China

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • C reactive protein

  • Janus kinase

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved